What is the translation of " RANDOMIZED TO RECEIVE " in Croatian?

• randomizirani u skupine koje su primale

Examples of using Randomized to receive in English and their translations into Croatian

Subjects randomized to receive erythropoietin N=251.
Ispitanici randomizirani da primaju eritropoetin N=251.

In a double-blind, controlled clinical study to evaluate the safety and biochemical efficacy of Respreeza 44 subjects were randomized to receive 60 mg/ kg bw intravenous dose of Respreeza once weekly for 24 weeks.
U dvostruko slijepom, kontroliranom kliničkom ispitivanju za procjenu sigurnosti i biokemijske djelotvornosti Respreeze 44 ispitanika bila su randomizirana kako bi primala intravensku dozu Respreeze od 60 mg/kg TT jednom tjedno tijekom 24 tjedna.

Subjects randomized to receive ribavirin dose reduction N=249.
Ispitanici randomizirani da primaju sniženu dozu ribavirina N=249.

In a separate study, a total of 413 patients undergoing initial and repeat cycles of chemotherapy(including carboplatin, cisplatin, oxaliplatin, and doxorubicin regimens), were randomized to receive either Akynzeo(n=309) or aprepitant and palonosetron n=104.
U odvojenom ispitivanju, ukupno 413 bolesnika koji su primali početni i ponavljane cikluse kemoterapije(uključujući protokole s karboplatinom, cisplatinom, oksaliplatinom i doksorubicinom) bili su randomizirani i primali su ili Akynzeo(n 309) ili aprepitant i palonozetron n 104.

On Day 3, those randomized to receive buprenorphine/naloxone were switched to the combination tablet.
Dana, ispitanici randomizirani u skupinu koja će primati buprenorfin/nalokson prebačeni su na kombiniranu tabletu.

A total of 180 subjects with alpha1-proteinase inhibitor deficiency characterized by a serum alpha1-proteinase inhibitor level< 11 μM(i.e.< 50 mg/dL as determined by nephelometry) and clinical evidence of emphysema, were randomized to receive a weekly 60 mg/ kg bw intravenous dose of either Respreeza(93 subjects) or placebo(87 subjects) for up to 24 months.
Ukupno je 180 ispitanika s nedostatkom inhibitora alfa1-proteinaze s razinom inhibitora alfa1-proteinaze u serumu< 11 μM(tj.< 50 mg/dl određeno nefelometrijom) i kliničkim dokazima emfizema bilo randomizirano kako bi primali tjednu intravensku dozu od 60 mg/kg TT Respreeze(93 ispitanika) ili placebo(87 ispitanika) tijekom najviše 24 mjeseca.

Study I patients were randomized to receive abatacept 2 or 10 mg/kg or placebo for 12 months.
U Ispitivanju I bolesnici su randomizirani da tijekom 12 mjeseci primaju abatacept u dozi od 2 ili 10 mg/kg, odnosno placebo.

Patients were randomized to receive either 20 mg/kg or 40 mg/kg once every two weeks for a period of 52 weeks.
Bolesnici su randomizirani u skupine koje su primale 20 mg/kg ili 40 mg/kg jedanput svaka dva tjedna tijekom 52 tjedna.

The TERRAIN study enrolled 375 chemo- and antiandrogen-therapy naïve patients who were randomized to receive either enzalutamide at a dose of 160 mg once daily(N 184) or bicalutamide at a dose of 50 mg once daily N 191.
Ispitivanje TERRAIN uključivalo je 375 bolesnika koji ranije nisu primali kemoterapiju niti antiandrogenu terapiju i koji su bili randomizirani u skupinu koja je primala enzalutamid u dozi od 160 mg jednom dnevno(N 184) ili u skupinu koja je primala bikalutamid u dozi od 50 mg jednom dnevno N 191.

Patients were randomized to receive either PegIntron(1.5 µg/kg/week) plus ribavirin(800 mg/day) or interferon alfa-2b(3 MIU TIW) plus ribavirin(800 mg/day) for.
Bolesnici su bili randomizirani u skupine koje su primale PegIntron(1, 5 μg/kg na tjedan) i ribavirin(800 mg na dan) ili interferon alfa-2b 3 mil.

Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age(2 to< 6 years, 6 to< 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Morali su imati početnu vrijednost HIV-1 RNA najmanje 1 500 kopija/ml, stratificirani su po dobi(od 2 do< 6 godina, od 6 do< 12 godina, te od 12 do 18 godina) i randomizirani na jedan od dvaju režima tipranavira s ritonavirom: doza od 375 mg/m2/150 mg/m2 ili 290 mg/m2/115 mg/m2, plus osnovna terapija s najmanje dva neproteazna antiretrovirusna lijeka, koji su bili optimizirani pomoću početnog testiranja genotipske rezistencije.

Patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg ustekinumab every 8 weeks, 90 mg ustekinumab every 12 weeks or placebo for 44 weeks for recommended maintenance posology, see section 4.2.
Bolesnici su bili randomizirani u skupine koje su primale supkutani režim održavanja od bilo 90 mg ustekinumaba svakih 8 tjedana, 90 mg ustekinumaba svakih 12 tjedana ili placebo tijekom 44 tjedna za preproučeno doziranje održavanja, vidjeti dio 4.2.

A total of 618 patients were randomized to receive 7 mg(n=205) or 14 mg(n=216) of teriflunomide or placebo n=197.
Ukupno 618 bolesnika randomizirano je kako bi primalo 7 mg(n=205) ili 14 mg(n=216) teriflunomida ili placebo n=197.

Patients were randomized to receive either pegylated interferon alfa-2b(100 or 150 µg/week based on weight) plus ribavirin(800-1,200 mg/day based on weight) or IntronA(3 MIU TIW) plus ribavirin 800-1,200 mg/day based on weight.
Bolesnici su bili randomizirani tako da su primali pegilirani interferon alfa-2b(100 ili 150 μg na tjedan, ovisno o tjelesnoj težini) i ribavirin(800-1200 mg na dan, ovisno o tjelesnoj težini) ili IntronA(3 milijuna IU triput na tjedan) i ribavirin 800-1200 mg na dan, ovisno o tjelesnoj težini.

In a double-blind, double-dummy, parallel-group study comparing buprenorphine ethanolic solution to a full agonist active control, 162 subjects were randomized to receive the ethanolic sublingual solution of buprenorphine at 8 mg/day(a dose which is roughly comparable to a dose of 12 mg/day of buprenorphine/naloxone), or two relatively low doses of active control, one of which was low enough to serve as an alternative to placebo, during a 3 to10 day induction phase, a 16-week maintenance phase and a 7-week detoxification phase.
U dvostruko slijepom ispitivanju s dvije kontrole na paralelnim skupinama, u kojem se uspoređivala etanolna otopina buprenorfina s aktivnom kontrolom punog agonista, 162 ispitanika su randomizirana primati sublingvalno 8 mg/dan etanolne otopine buprenorfina(doza koja je ugrubo usporediva s dozom od 12 mg/dan buprenorfina/naloksona), ili dvije relativno niske doze aktivne kontrole, od kojih je jedna bila dovoljno niska da služi kao alternativa placebu, tijekom 3 do 10 dana faze uvođenja, 16 tjedana faze održavanja i 7 tjedana faze detoksikacije.

Patients were randomized to receive either pegylated interferon alfa-2b(1.5 µg/kg/week) plus ribavirin(800 mg/day) or IntronA(3 MIU TIW) plus ribavirin(800 mg/day) for 48 weeks with a follow-up period of 6 months.
Bolesnici su bili randomizirani u skupine koje su primale pegilirani interferon alfa-2b(1, 5 μg/kg na tjedan) i ribavirin(800 mg na dan) ili IntronA(3 milijuna IU triput na tjedan) i ribavirin(800 mg na dan) tijekom 48 tjedana, uz razdoblje praćenja od 6 mjeseci.

The SVR rates in subjects randomized to receive ribavirin dose reduction and randomized to receive erythropoietin were comparable.
Stope SVR-a u bolesnika randomiziranih da primaju sniženu dozu ribavirina bile su slične onima u bolesnika randomiziranih da primaju eritropoetin.

Patients were randomized to receive injections of ZYPADHERA 405 mg every 4 weeks, 300 mg every 2 weeks, 210 mg every 2 weeks, or placebo every 2 weeks.
Bolesnici su randomizirani u skupine koje su primale injekcije lijeka ZYPADHERA od 405 mg svaka 4 tjedna, 300 mg svaka 2 tjedna, 210 mg svaka 2 tjedna ili placebo svaka 2 tjedna.

One hundred eighty six patients were randomized to receive docetaxel(100 mg/m2) with or without trastuzumab; 60% of patients received prior anthracycline-based adjuvant chemotherapy.
Randomizirano je 186 bolesnika koji su primali docetaksel(100 mg/m2) s trastuzumabom ili bez trastuzumaba, a 60% bolesnika ranije je primalo adjuvantnu terapiju temeljenu na antraciklinima.

Patients were randomized to receive Enzepi or matching placebo for 6 to 7 days of treatment, followed by cross-over to the alternate treatment for an additional 6 to 7 days.
Bolesnici su bili randomizirani u skupinu koja je dobivala Enzepi ili odgovarajući placebo tijekom 6 do 7 dana liječenja, nakon čega je uslijedio prelazak na drukčije liječenje tijekom dodatnih 6 do 7 dana.

Study V patients were randomized to receive this same fixed dose of abatacept or 3 mg/kg infliximab or placebo for 6 months.
U Ispitivanju V bolesnici su randomizirani tako da su tijekom 6 mjeseci primali abatacept u istoj toj fiksnoj dozi, infliksimab u dozi od 3 mg/kg ili placebo.

Patients were randomized to receive Enzepi from an opened capsule mixed and administered with apple juice(in a syringe nurser) or apple sauce(using a spoon) for 10 days of treatment, followed by a cross-over to the alternate mode of administration for an additional 10 days.
Bolesnici su bili randomizirani u skupine koje su primale Enzepi iz otvorene kapsule promiješane i primijenjene sa sokom od jabuke(oralnom štrcaljkom za hranjenje) ili pireom od jabuke(žlicom) tijekom 10 dana liječenja, nakon čega je uslijedio prelazak na drukčiji način primjene tijekom drugih 10 dana.

Patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg ustekinumab every 8 weeks, 90 mg ustekinumab every 12 weeks or placebo for 44 weeks for recommended maintenance posology, see section 4.2 of the STELARA Solution for injection(vial) and Solution for injection in pre filled syringe SmPC.
Bolesnici su bili randomizirani u skupine koje su primale supkutani režim održavanja od bilo 90 mg ustekinumaba svakih 8 tjedana, 90 mg ustekinumaba svakih 12 tjedana ili placebo tijekom 44 tjedna za preproučeno doziranje održavanja, vidjeti dio 4.2 sažetka opisa svojstava lijeka STELARA otopine za injekciju(bočica) i otopine za injekciju u napunjenoj štrcaljki.